Clinical Trial Update: Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating neoadjuvant durvalumab alone or with novel agents in resectable early-stage non-small cell lung cancer has completed with post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: MedImmune LLC | Conditions: Resectable, Early-stage | Phase 2 | Status: COMPLETED | Results posted: 2022-02-24